BrainStorm announced that it has submitted as special protocol assessment, or SPA, request to the FDA for a Phase 3b study of NurOwn, its investigational treatment for amyotrophic lateral sclerosis, or ALS.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BCLI:
